Antipsychotic-induced weight gain: a comprehensive research synthesis

DB Allison, JL Mentore, M Heo… - American journal of …, 1999 - Am Psychiatric Assoc
DB Allison, JL Mentore, M Heo, LP Chandler, JC Cappelleri, MC Infante, PJ Weiden
American journal of Psychiatry, 1999Am Psychiatric Assoc
OBJECTIVE: The purpose of this study was to estimate and compare the effects of
antipsychotics—both the newer ones and the conventional ones—on body weight.
METHOD: A comprehensive literature search identified 81 English-and non-English-
language articles that included data on weight change in antipsychotic-treated patients. For
each agent, a meta-analysis and random effects metaregression estimated the weight
change after 10 weeks of treatment at a standard dose. A comprehensive narrative review …
OBJECTIVE
The purpose of this study was to estimate and compare the effects of antipsychotics—both the newer ones and the conventional ones—on body weight.
METHOD
A comprehensive literature search identified 81 English- and non-English-language articles that included data on weight change in antipsychotic-treated patients. For each agent, a meta-analysis and random effects metaregression estimated the weight change after 10 weeks of treatment at a standard dose. A comprehensive narrative review was also conducted on all articles that did not yield quantitative information but did yield important qualitative information.
RESULTS
Placebo was associated with a mean weight reduction of 0.74 kg. Among conventional agents, mean weight change ranged from a reduction of 0.39 kg with molindone to an increase of 3.19 kg with thioridazine. Among newer antipsychotic agents, mean increases were as follows: clozapine, 4.45 kg; olanzapine, 4.15 kg; sertindole, 2.92 kg; risperidone, 2.10 kg; and ziprasidone, 0.04 kg. Insufficient data were available to evaluate quetiapine at 10 weeks.
CONCLUSIONS
Both conventional and newer antipsychotics are associated with weight gain. Among the newer agents, clozapine appears to have the greatest potential to induce weight gain, and ziprasidone the least. The differences among newer agents may affect compliance with medication and health risk.
Psychiatry Online
以上显示的是最相近的搜索结果。 查看全部搜索结果